Format

Send to

Choose Destination
Eur Radiol. 2017 Apr;27(4):1776-1782. doi: 10.1007/s00330-016-4504-2. Epub 2016 Jul 19.

Feasibility of a 2nd generation MR-compatible manipulator for transrectal prostate biopsy guidance.

Author information

1
Department of Radiology, route 766, Radboud University Nijmegen Medical Center, P.O Box 9101, 6500HB, Nijmegen, The Netherlands. Joyce.Bomers@radboudumc.nl.
2
Department of Radiology, route 766, Radboud University Nijmegen Medical Center, P.O Box 9101, 6500HB, Nijmegen, The Netherlands.
3
Soteria Medical, Arnhem, The Netherlands.
4
MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.

Abstract

OBJECTIVES:

To assess the feasibility of a 2nd generation MR-compatible, remote-controlled manipulator (RCM) as an aid to perform MR-guided transrectal prostate biopsy in males with suspicion of prostate cancer (PCa).

METHODS:

This prospective phase I study was approved by the local ethical committee and written informed consent was obtained from each patient. Twenty patients with ≥1 cancer suspicious region (CSR) with a PI-RADS score of ≥3 detected on the diagnostic multi-parametric MRI and no prior prostate treatment underwent MR-guided biopsy with the aid of the RCM. Complications were classified according to the modified Clavien system for reporting surgical complications. For evaluation of the workflow, procedure- and manipulation times were recorded.

RESULTS:

All CSR's (n=20) were reachable with the MR-compatible RCM and the cancer detection rate was 70 %. The median procedure time was 36:44 minutes (range, 23 - 61 minutes) and the median manipulation time for needle guide movement was 5:48 minutes (range, 1:15 - 18:35 minutes). Two Clavien grade 1 complications were reported.

CONCLUSIONS:

It is feasible and safe to perform transrectal MR-guided prostate biopsy using a MR-compatible RCM as an aid. It is a fast and efficient way to biopsy suspicious prostate lesions with a minimum number of biopsies per patient.

KEY POINTS:

• It is feasible to perform transrectal prostate biopsy using a MR-compatible RCM. • Using a RCM for MR-guided biopsy is safe, fast, and efficient. • All cancer suspicious regions were reachable with the RCM.

KEYWORDS:

Biopsy; Feasibility; MRI; Prostate cancer; Robotics

PMID:
27436021
PMCID:
PMC5334446
DOI:
10.1007/s00330-016-4504-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center